Sponsored message
Logged in as
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
  • Listen Now Playing Listen
NPR News

The weight loss drug Wegovy may do more than help people lose weight

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today.

Listen 2:37
Listen to the Story

SARAH MCCAMMON, HOST:

The maker of Wegovy is claiming the weight loss drug can also cut the risk of heart attacks and strokes. NPR's Allison Aubrey reports.

ALLISON AUBREY, BYLINE: It's no secret that Wegovy, like its counterpart Ozempic, is in high demand. These drugs are very effective at helping people control appetite and manage weight. Now, Novo Nordisk, the maker of Wegovy, has results from a five-year study that show people with obesity or who are overweight that take the drug have about a 20% reduced risk of having a major cardiac event, such as a heart attack or stroke. Here's physician Steven Nissen, a cardiologist at the Cleveland Clinic who was not involved in the study.

STEVEN NISSEN: This is a very promising result, but how promising will depend on other things.

AUBREY: The results of the study, which included about 17,000 adults, have not yet been published in a peer-reviewed journal. And Dr. Nissen says key details such as potential risks are not included in the company's press release. He says the reduction in heart attacks and strokes seems very significant.

NISSEN: We now know that there is a benefit, and that's great, but we don't know what the risks are. And it's always about benefit versus risk with any drug, and we need to see all of that.

AUBREY: Dr. Nissen is studying a similar drug, Mounjaro, in an ongoing clinical trial. Dr. Pamela Brandt of Inova Health System treats patients with obesity and says Wegovy does have some common side effects.

Sponsored message

PAMELA BRANDT: People feel full much more quickly but that can also lead to nausea or an increase in acid reflux or feeling just uncomfortably full.

AUBREY: Rare side effects include the risk of pancreatitis and, in rodent studies, a risk of thyroid tumors. So doctors screen patients for a family history of a specific kind of thyroid cancer. The findings of the new study come amid a debate about whether Medicare should pay for the blockbuster weight loss drugs. And Dr. Brandt says the new research shows that weight loss for these patients is not about vanity or appearances. It's about preventing disease.

BRANDT: The whole goal of treating people to help them achieve weight loss is to make them healthier. So seeing that they actually have a decreased risk of cardiovascular events like heart attacks and strokes, that's what's really important.

AUBREY: Brandt says she looks forward to seeing all the details and what could be a landmark study.

Allison Aubrey, NPR News.

(SOUNDBITE OF COSMONKEY'S "SAN MARINO") Transcript provided by NPR, Copyright NPR.

You come to LAist because you want independent reporting and trustworthy local information. Our newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our connected community. We are free to tell the full truth, to hold power to account without fear or favor, and to follow facts wherever they lead. Our only loyalty is to our audiences and our mission: to inform, engage, and strengthen our community.

Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive from readers like you will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.

If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.

Your tax-deductible donation keeps LAist independent and accessible to everyone.
Senior Vice President News, Editor in Chief

Make your tax-deductible donation today